Skip to content
AstraZeneca Pharma logo

AstraZeneca Pharma

ASTRAZEN NSE
₹6,368.00 +23.00 (+0.36%)
P/E
93.85
View as Markdown
MCP
Close 4 Nov 2026 ₹6,368.00 −2,814.50 −30.7% 1Y
Start ₹9,182.50

Key Fundamentals

SmallcapPharmaceuticals & BiotechnologyHealthcare

Price-based figures as of · EPS basis: Standalone · TTM

ROCE
29.30%
Debt to Equity
0.13
EPS (TTM)
₹67.85
Book Value
₹349.12
Market Cap
—
P/E (TTM)
93.85
P/B
18.24
ROE
23.30%
Dividend Yield
0.57%
EBITDA
₹291 Cr
52W High
₹9,580.00
52W Low
₹5,640.00
Day Range
₹6,297.00 – ₹6,404.50
Volume
2,807

Peer Comparison

Healthcare › Pharmaceuticals

AstraZeneca Pharma peer comparison
Sun Pharma
₹1,773.4038.81₹4,29,049 Cr4.770.90%16.00%20.50%₹61,631 Cr₹10,987 Cr
Divis Laboratories
₹10,037.5091.10₹2,65,269 Cr15.900.30%16.50%22.00%₹11,230 Cr₹2,925 Cr
Torrent Pharmaceuticals
₹4,738.5078.61₹1,77,061 Cr9.810.82%27.40%15.20%₹17,400 Cr₹2,099 Cr
Zydus Life Science
₹1,188.1026.44₹1,25,446 Cr4.370.08%21.20%21.10%₹28,592 Cr₹4,593 Cr
Laurus Labs
₹2,323.80114.81₹1,25,228 Cr20.720.04%18.30%17.80%₹7,270 Cr₹1,090 Cr
Dr Reddys Laboratories
₹1,374.0035.59₹1,14,543 Cr2.960.58%11.20%13.00%₹33,228 Cr₹3,184 Cr
Cipla
₹1,402.0033.59₹1,12,454 Cr3.200.93%11.60%15.50%₹28,324 Cr₹3,356 Cr
AstraZeneca Pharma (this company)
₹6,368.0093.85₹15,834 Cr18.240.57%23.30%29.30%₹2,432 Cr₹170 Cr
Median 8 companies₹2,048.6058.71₹1,25,337 Cr7.290.58%17.40%19.15%₹22,862 Cr₹3,055 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

Overall score

42 Weak

Data confidence 100/100

Category scores

Quality
38
Weak
Returns, margins, earnings quality 22% weight
Valuation
21
Poor
Cheap vs sector & own history 24% weight
Growth
81
Strong
Sales & profit trajectory 9% weight
Financial Health
68
Strong
Solvency, leverage, coverage 9% weight
Momentum
14
Poor
Trend strength, vol-adjusted 12% weight
Ownership
64
Good
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

1
  • Company has been maintaining a healthy dividend payout of 51.4%

Weaknesses

1
  • Stock is trading at 17.1 times its book value

Technical Indicators

Technical signals: verdict and indicator counts
GroupSignalBearishNeutralBullish
OverallBearish937
OscillatorsNeutral333
Moving AveragesStrong Bearish604

Key readings

RSI (14)
56.19
Neutral
MACD (12,26,9)
−27.20
Bullish
SMA (50)
6,452.26
Bearish
SMA (200)
7,891.23
Bearish

As of

Growth Rate

From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Jun 2026 against Jun 2025.

Revenue

Revenue growth by window
10Y+14.97%
5Y+22.83%
3Y+31.41%
1Y+32.63%
TTM+31.23%

Net profit

Net profit growth by window
10Y+43.72%
5Y+15.12%
3Y+23.83%
1Y+62.07%
TTM−7.10%

Operating cash flow

Operating cash flow growth by window
10YTurned negative
5YTurned negative
3YTurned negative
1YTurned negative
TTM—

TTM: Reported once a year, so there is no trailing-twelve-month figure.

Operating margin· change in pp

Operating margin growth by window
10Y+8.67 pp
5Y−5.07 pp
3Y−4.94 pp
1Y−3.29 pp
TTM−6.57 pp

Revenue by year

Revenue by year, ₹ crore
Mar 2017₹544 Cr
Mar 2018₹571 Cr
Mar 2019₹728 Cr
Mar 2020₹832 Cr
Mar 2021₹814 Cr
Mar 2022₹806 Cr
Mar 2023₹1,003 Cr
Mar 2024₹1,296 Cr
Mar 2025₹1,716 Cr
Mar 2026₹2,276 Cr

Net profit by year

Net profit by year, ₹ crore
Mar 2017₹20.00 Cr
Mar 2018₹26.00 Cr
Mar 2019₹54.00 Cr
Mar 2020₹72.00 Cr
Mar 2021₹93.00 Cr
Mar 2022₹62.00 Cr
Mar 2023₹99.00 Cr
Mar 2024₹162 Cr
Mar 2025₹116 Cr
Mar 2026₹188 Cr

AI Analysis — Bull vs Bear

Figures as of 28 Oct 2026
AI opinion · based on fundamentals
Risk high

Astrazeneca Pharma India Ltd trades at ₹6,237 as of 2026-10-28 with a market cap of ₹15,592.5 Cr. The company delivers strong revenue growth (31% TTM sales CAGR) and maintains a healthy ROE of 21.49%, but profitability has contracted with TTM profit declining 18% while the stock trades at a PE of 91.92x and 17.86x book value.

Bull Case 8
  • Exceptional revenue momentum with compounded sales CAGR of 31% on a TTM basis and 31% over 3 years, indicating sustained top-line acceleration
  • Consistently high return on equity at 21.49% currently, with a 5-year average of 22% and 10-year average of 21%, reflecting durable capital efficiency
  • Strong ROCE of 25.48% suggests the business generates attractive returns on total capital employed, well above cost of capital for most Indian firms
  • Near-zero leverage with a debt-to-equity ratio of just 0.13, providing significant financial flexibility and low balance sheet risk
  • Healthy dividend payout ratio of 51.4% with a current yield of 0.59%, demonstrating shareholder-friendly capital allocation
  • Long-term compounded profit growth of 43% over 10 years shows the business has scaled earnings meaningfully over a full cycle
  • Stock price CAGR of 20% over 10 years and 14% over 5 years reflects long-term wealth creation despite recent correction
  • Backed by global parent AstraZeneca PLC, providing access to a strong pipeline of patented drugs, R&D capabilities, and established brand credibility in the Indian healthcare market
Bear Case 7
  • TTM earnings have declined 18% year-over-year despite 31% revenue growth, pointing to significant margin compression or one-off cost pressures
  • PE ratio of 91.92x TTM is extremely elevated, requiring sustained high-growth execution to justify current valuation levels
  • Stock has fallen 35% over the past 1 year and trades 36.7% below its 52-week high of ₹9,849.5, indicating severe negative momentum
  • Dividend yield of just 0.59% offers minimal income cushion despite the 51.4% payout ratio, reflecting the high price relative to earnings
  • 3-year compounded profit CAGR of 15% lags the 3-year sales CAGR of 31%, suggesting operating leverage is not translating into proportional profit growth
  • EPS of ₹67.85 TTM against a share price of ₹6,237 implies the market is pricing in multi-year aggressive growth that may not materialise
  • As a subsidiary of a multinational parent, key strategic decisions including product launches, pricing, and capital allocation are driven by global priorities that may not always align with minority shareholder interests

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

9h ago

TL;DR: AstraZeneca Pharma India is investing in physical infrastructure with a new 25,600 sq ft Mumbai office, signaling confidence in its India growth trajectory. The ₹151 crore NPPA dispute remains a latent risk, though the court stay until January 2027 removes near-term financial impact. A solid ESG score of 73 reflects reasonable governance standards. The outlook is stable, but the NPPA case resolution post-2027 warrants monitoring.

Positives 1
  • New Mumbai corporate office Oct 16

    AstraZeneca Pharma India inaugurated a 25,600 sq ft corporate office in Mumbai to support expanding clinical trial and commercial operations.

Neutral 2
  • NPPA ₹151 crore recovery stayed Nov 02

    Delhi High Court stayed NPPA coercive recovery of ₹151.20 crore alleged overcharging on Symbicort Turbuhaler until January 11, 2027. Alleged violations span May 2016 to November 2025 under DPCO, 2013.

  • ESG rating of 73 for FY26 Oct 16

    AstraZeneca Pharma India received an ESG rating of 73 for FY26, independently assigned based on public disclosures.

Quarterly Results

₹ Cr
ASTRAZEN quarterly results, ₹ crore
Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
295
311
306
383
388
408
440
480
526
559
612
579
683
Expenses
228
258
291
334
349
355
363
394
445
484
567
518
634
Operating Profit
67
53
15
49
38
53
77
86
81
75
45
61
49
OPM %
23%
17%
4.9%
13%
10%
13%
17%
18%
15%
13%
7%
11%
7%
Other Income
8
25
10
9
−49
8
−26
10
11
1
7
5
9
Interest
0
0
1
0
0
0
0
1
1
1
1
2
2
Depreciation
4
4
4
4
4
9
9
18
17
3
4
6
5
PBT
71
73
20
54
−15
51
42
78
75
73
47
58
51
Tax %
25%
29%
23%
27%
−22%
25%
27%
26%
25%
26%
30%
23%
25%
Net Profit
54
52
16
39
−12
38
31
58
56
54
33
45
38
EPS (₹)
21.54
20.95
6.32
15.79
−4.72
15.37
12.34
23.3
22.33
21.69
13.04
17.95
15.17

Profit & Loss

₹ Cr
ASTRAZEN profit and loss, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
517
564
544
571
728
832
814
806
1,003
1,296
1,716
2,276
2,432
Expenses
528
547
506
525
657
711
678
719
838
1,111
1,462
2,014
2,202
Operating Profit
−11
16
37
46
71
121
135
86
165
184
254
262
230
OPM %
−2.2%
2.9%
7%
8%
10%
15%
17%
11%
16%
14%
15%
12%
9%
Other Income
6
7
14
12
16
13
13
15
−14
51
−56
23
21
Interest
0
0
0
0
0
1
1
1
1
1
1
4
6
Depreciation
15
17
16
15
15
19
20
17
16
15
40
29
17
PBT
−21
6
36
44
73
114
127
83
134
220
156
252
228
Tax %
0%
9%
44%
41%
25%
37%
27%
26%
26%
26%
26%
26%
—
Net Profit
−21
5
20
26
54
72
93
62
99
162
116
188
170
EPS (₹)
−8.34
2.1
8.02
10.36
21.78
28.88
37.32
24.64
39.72
64.6
46.3
75.01
67.85
Div. Payout %
0%
0%
0%
0%
0%
3%
5%
41%
40%
37%
69%
48%
—

Balance Sheet

₹ Cr
ASTRAZEN balance sheet, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
5
5
5
5
5
5
5
5
5
5
5
5
Reserves
146
151
218
242
296
359
451
506
584
707
765
868
Borrowings
0
0
0
0
0
12
12
9
7
5
36
111
Other Liabilities
261
247
193
214
261
330
306
337
389
362
712
1,006
Total Liabilities
412
403
415
461
562
706
775
857
985
1,078
1,518
1,989
Fixed Assets
101
97
87
75
75
72
81
74
69
67
64
117
CWIP
12
6
5
4
7
24
4
2
1
0
0
0
Investments
0
0
0
0
0
0
0
0
0
0
0
0
Other Assets
298
299
324
382
480
611
690
780
915
1,011
1,454
1,872
Total Assets
412
403
415
461
562
706
775
857
985
1,078
1,518
1,989

Cash Flow

₹ Cr
ASTRAZEN cash flow, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
−46
57
38
9
55
87
105
101
58
28
65
−15
Investing
−19
−4
0
−9
4
−171
173
5
18
22
31
19
Financing
0
−1
0
0
0
−6
−9
−9
−24
−44
−66
−92
Net Cash Flow
−64
53
38
−1
59
−90
269
96
52
5
31
−88
Free Cash Flow
−69
48
33
3
37
74
99
94
53
18
64
−18
CFO/EBITDA
393
365
133
28
126
100
101
146
60
46
51
26

Ratios

ASTRAZEN financial ratios, annual
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
30
54
29
35
40
37
38
39
39
43
39
34
Inventory Days
157
141
121
229
186
197
198
164
193
140
208
272
Days Payable
203
174
184
257
266
251
221
223
231
121
173
207
Cash Conversion Cycle
−16
21
−34
7
−39
−17
15
−20
1
62
74
99
Working Capital Days
−15
−28
−36
−8
−14
−16
−17
−34
−18
20
22
50
ROCE %
−13%
4%
15%
19%
27%
34%
30%
16%
31%
31%
33%
29%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view AstraZeneca Pharma insights

60 extracted metrics across FY11–FY27.

Shareholding Pattern

As of Sep 2026

  • Promoters 75.00%
  • Public 12.82%
  • DIIs 7.09%
  • FIIs 2.64%
  • Others 2.45%

No promoter shares pledged as of Sep 2026

Change vs previous quarter

Not shown for some quarters: Others. Not available separately for this quarter: the shareholding filing gives Public and Others as one figure, shown under Public, so Others is left blank rather than estimated.

Documents

Frequently Asked Questions about AstraZeneca Pharma

What does Astrazeneca Pharma India Ltd do?
AstraZeneca Pharma India Ltd is engaged in the business of manufacture, distribution and marketing of pharmaceutical products.
Where is Astrazeneca Pharma India Ltd (ASTRAZEN) listed?
Astrazeneca Pharma India Ltd trades as ASTRAZEN on the NSE and under code 506820 on the BSE.
Which sector does Astrazeneca Pharma India Ltd belong to?
Astrazeneca Pharma India Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the PE ratio of Astrazeneca Pharma India Ltd?
Astrazeneca Pharma India Ltd trades at a PE ratio of 93.85 as of 4 Nov 2026, on earnings per share of ₹67.85, against a book value of ₹349.12 per share.
What is the 52-week high and low of Astrazeneca Pharma India Ltd?
Over the last 52 weeks Astrazeneca Pharma India Ltd has traded between ₹5,640 and ₹9,580 as of 4 Nov 2026.
Does Astrazeneca Pharma India Ltd pay dividends?
Astrazeneca Pharma India Ltd has a dividend yield of 0.57%.
What is the Return on Equity (ROE) of Astrazeneca Pharma India Ltd?
Astrazeneca Pharma India Ltd reported a return on equity of 23.30%. Its debt-to-equity ratio is 0.13.

Company Information

AstraZeneca Pharma India Ltd is engaged in the business of manufacture, distribution and marketing of pharmaceutical products.

Website astrazenecaindia.com
CEO Ms. Bhavana Agrawal
Employees 600
Listed 4 May 2001
Face Value ₹2

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/ASTRAZEN.md for Astrazeneca Pharma India Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Pharma stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month